Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope.
PD-1
PD-L1
RNAscope
diffuse large B-cell lymphoma
dog
Journal
Veterinary sciences
ISSN: 2306-7381
Titre abrégé: Vet Sci
Pays: Switzerland
ID NLM: 101680127
Informations de publication
Date de publication:
29 Jun 2021
29 Jun 2021
Historique:
received:
27
05
2021
revised:
24
06
2021
accepted:
28
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Immune checkpoints are a set of molecules dysregulated in several human and canine cancers and aberrations of the PD-1/PD-L1 axis are often correlated with a worse prognosis. To gain an insight into the role of immune checkpoints in canine diffuse large B-cell lymphoma (cDLBCL), we investigated PD-L1, PD-1 and CD8A expression by RNAscope. Results were correlated with several clinico-pathological features, including treatment, Ki67 index and outcome. A total of 33 dogs treated with chemotherapy (
Identifiants
pubmed: 34209830
pii: vetsci8070120
doi: 10.3390/vetsci8070120
pmc: PMC8310184
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Ministry of Health
ID : RC IZS VE 04/2020
Références
PLoS One. 2016 Jun 08;11(6):e0157176
pubmed: 27276060
In Vivo. 2016 May-Jun;30(3):195-204
pubmed: 27107075
Vet Immunol Immunopathol. 2021 Feb;232:110169
pubmed: 33387703
Nat Rev Cancer. 2019 Dec;19(12):667-685
pubmed: 31645711
Res Vet Sci. 2019 Aug;125:130-135
pubmed: 31212200
Sci Rep. 2020 Oct 27;10(1):18311
pubmed: 33110170
J Immunother Cancer. 2019 Jun 7;7(1):146
pubmed: 31174615
Vet Comp Oncol. 2017 Jun;15(2):534-549
pubmed: 26842912
J Cancer. 2021 Mar 5;12(9):2735-2746
pubmed: 33854633
Life Sci. 2020 Oct 15;259:118297
pubmed: 32822718
Clin Chem. 2019 Oct;65(10):1228-1238
pubmed: 31315901
Sci Rep. 2020 Feb 7;10(1):2083
pubmed: 32034198
Int J Mol Sci. 2019 Mar 15;20(6):
pubmed: 30884772
Vet Immunol Immunopathol. 2018 Apr;198:19-25
pubmed: 29571514
PLoS One. 2014 Jun 10;9(6):e98415
pubmed: 24915569
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Vet Comp Oncol. 2014 Mar;12(1):29-36
pubmed: 22489798
Vet Comp Oncol. 2018 Sep;16(3):352-360
pubmed: 29380929
Leuk Res. 2018 Apr;67:45-55
pubmed: 29428449
Vet Immunol Immunopathol. 2020 Dec;230:110142
pubmed: 33129194
PLoS One. 2018 Apr 24;13(4):e0195357
pubmed: 29689086
Sci Rep. 2017 Aug 21;7(1):8951
pubmed: 28827658
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6640-6650
pubmed: 32161124
PLoS One. 2013 Sep 04;8(9):e72591
pubmed: 24023754
Cancer Res. 2013 Aug 15;73(16):5029-39
pubmed: 23783577
J Comp Pathol. 2014 Nov;151(4):322-8
pubmed: 25172054
Front Vet Sci. 2021 Mar 17;8:647009
pubmed: 33816589
Front Vet Sci. 2016 Aug 31;3:77
pubmed: 27630997
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Vet J. 2016 Jan;207:20-28
pubmed: 26545847
PLoS One. 2014 Nov 05;9(11):e111817
pubmed: 25372838
Vet Comp Oncol. 2010 Mar;8(1):28-37
pubmed: 20230579
BMC Vet Res. 2013 May 03;9:94
pubmed: 23641796
PLoS One. 2016 Feb 19;11(2):e0148366
pubmed: 26894679
Haematologica. 2019 Jun;104(6):e256-e259
pubmed: 30545928
Curr Opin Hematol. 2017 Jul;24(4):359-366
pubmed: 28426554
Front Vet Sci. 2020 Jun 11;7:330
pubmed: 32596272
Hematol Oncol. 2019 Aug;37(3):314-315
pubmed: 30835862
Histopathology. 2019 Mar;74(4):618-628
pubmed: 30286249
J Mol Diagn. 2012 Jan;14(1):22-9
pubmed: 22166544